-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15

Benzinga·11/06/2026 16:18:03
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.